Financial Comparison: Sinovac Biotech (SVA) vs. Myovant Sciences (MYOV)

Sinovac Biotech (NASDAQ: SVA) and Myovant Sciences (NYSE:MYOV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Sinovac Biotech and Myovant Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Myovant Sciences N/A -53.75% -48.90%

Institutional and Insider Ownership

31.8% of Sinovac Biotech shares are held by institutional investors. Comparatively, 79.2% of Myovant Sciences shares are held by institutional investors. 2.8% of Myovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Sinovac Biotech and Myovant Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech 0 0 0 0 N/A
Myovant Sciences 0 0 4 0 3.00

Myovant Sciences has a consensus target price of $22.50, indicating a potential upside of 61.41%. Given Myovant Sciences’ higher possible upside, analysts plainly believe Myovant Sciences is more favorable than Sinovac Biotech.

Earnings and Valuation

This table compares Sinovac Biotech and Myovant Sciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $72.43 million 6.25 -$590,000.00 $0.32 24.81
Myovant Sciences N/A N/A -$83.44 million ($1.41) -9.89

Sinovac Biotech has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Sinovac Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Sinovac Biotech beats Myovant Sciences on 6 of the 10 factors compared between the two stocks.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply